We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Escalon Acquires About 94% of Drew Scientific

By Labmedica staff writers
Posted on 06 Oct 2004
The acquisition of approximately 93.7% of the ordinary shares outstanding of Drew Scientific Group plc (Cumbria, UK) has been announced by Escalon Medical Corp. (Wayne, PA, USA). Escalon states that its revised purchase offer is now closed. The company intends to use the procedure established under United Kingdom law to compulsorily acquire any remaining shares of Drew.

Drew Scientific, although UK-based, has additional manufacturing operations in Texas and Connecticut (both in the USA). This diagnostics company specializes in the design, manufacture, sale, and distribution of analytic systems for laboratory testing worldwide. Drew provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases, and hematology, as well as veterinary hematology and blood chemistry

Escalon markets and distributes ophthalmic diagnostics, surgical and pharmaceutical products as well as vascular access devices. The company seeks to further diversity its product line to achieve critical mass in sales and take better advantages of its distribution capabilities through internal product development, acquisitions, or strategic partnerships.



Related Links:
Drew Scientific
Escalon

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
Automated Coagulation Analyzer
Hemolumi H6

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
06 Oct 2004  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
06 Oct 2004  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
06 Oct 2004  |   Industry



PURITAN MEDICAL